NasdaqGM - Delayed Quote ? USD Mural Oncology plc (MURA) Follow Compare 3.3700 0.0000 (0.00%) At close: November 21 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced solid tumors, including in platinum-resistant ovarian cancer (PROC), which does not typically respond to immunotherapies Safety profile and anti-tumor activity observed in ARTISTRY-1 supported the company’s two potentially registrational trials, with readouts expected in late Q1/earl GlobeNewswire ? yesterday MURA 0.00% Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural’s IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc GlobeNewswire ? 8 days ago MURA 0.00% Mural Oncology to Participate in Two Upcoming Investor Conferences WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences. Jefferies London Healthcare Conference 1x1 meetings with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Med GlobeNewswire ? 10 days ago MURA 0.00% Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on November 1, the Company granted to five newly hired employees (i) non-statutory stock options to purchase an aggregate of 23,500 ordinary shares of the Company and (ii) restricted stock units with GlobeNewswire ? 17 days ago MURA 0.00% Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced three upcoming poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 6-10, 2024 in Houston. The company will present tumor microenvironmen GlobeNewswire ? last month MURA 0.00% Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatme GlobeNewswire ? last month MURA 0.00% Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company’s Nominating and Corp GlobeNewswire ? last month MURA 0.00% Mural Oncology to Host First Virtual Investor Day on September 26, 2024 Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new cytokine-based immunotherapies Mural remains on track to deliver key data readouts in potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025 WALTHAM, Mass. and DUBLIN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasda GlobeNewswire ? 2 months ago MURA 0.00% We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 2 months ago MURA 0.00% Mural Oncology to Present at Two Upcoming Investor Conferences WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of its management team will participate at two upcoming investor conferences and take 1x1 meetings. A webcast of both presentations will be available at ir.muraloncology.com. Morgan Stanley GlobeNewswire ? 2 months ago MURA 0.00% Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On track to report readouts from Mural’s lead asset, nemvaleukin alfa, in two late-stage clinical trials in 1H 2025 Presented clinical data from ARTISTRY-3 on less frequent dosing of nemvaleukin at the American Society of Clinical Oncology annual meeting in June; newly recommended phase 2 dose is already in GlobeNewswire ? 3 months ago MURA 0.00% Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. “George has been a leader in business development for 30 years. There has been a great deal of industry interest i GlobeNewswire ? 3 months ago MURA 0.00% Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast will be available at www.threepartadvisors.com/east-coast and ir.muraloncol GlobeNewswire ? 5 months ago MURA 0.00% Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested Less frequent dosing regimen, a shift from five daily infusions to two infusions per three-week cycle, is being evaluated as both a single agent and in combination with pembrolizumab in patients with cutaneous melanoma in ARTISTRY-6. Preliminary dat GlobeNewswire ? 5 months ago MURA 0.00% Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin is also being evaluated both as a single agent and in combination with pembrolizumab in patients with cutaneous melanoma with preliminary data readouts anticipated in 2025 In April 2024, Mural presented preclinical data on its investigational GlobeNewswire ? 6 months ago MURA 0.00% Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced an upcoming poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4 in Chicago. The details are as follows: Recommended phase 2 dose (R GlobeNewswire ? 6 months ago MURA 0.00% Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects in preclinical models Data presented suggest dual-targeted, subunit approach to engineered IL-12 may mitigate cytokine’s hallmark toxicity without compromising efficacy WALTHAM, Mass and DUBLIN, Ireland, A GlobeNewswire ? 7 months ago MURA 0.00% Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company’s ongoing phase 2 trial in patients with melanoma Mural Oncology intends to nominate development candidates for its engineered therapies tar GlobeNewswire ? 7 months ago MURA 0.00% Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San Diego. The presentations will be the first time Mural will share preclinical GlobeNewswire ? 8 months ago MURA 0.00% Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that CEO Caroline Loew, Ph.D. will present at the TD Cowen 44th Annual Health Care Conference on March 5th at 10:30am ET. A live webcast of the presentation will be available at ir.muraloncology.com/events-and-pre GlobeNewswire ? 8 months ago MURA 0.00% Performance Overview Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return MURA S&P 500 YTD -43.07% +24.72% 1-Year -5.07% +30.47% 3-Year -5.07% +30.47%
